TY - JOUR
T1 - A European survey of antibiotic management of methicillin-resistant staphylococcus aureus infection
T2 - Current clinical opinion and practice
AU - Dryden, M.
AU - Andrasevic, A. T.
AU - Bassetti, M.
AU - Bouza, E.
AU - Chastre, J.
AU - Cornaglia, G.
AU - Esposito, S.
AU - French, G.
AU - Giamarellou, H.
AU - Gyssens, I. C.
AU - Nathwani, D.
AU - Unal, S.
AU - Voss, A.
N1 - Funding Information:
Editorial support for the supplement was provided by J. Turner at PAREXEL and was funded by Pfizer International Operations.
Funding Information:
M. Dryden is General Secretary of the British Society of Antimicrobial Chemotherapy. He has been an investigator in clinical trials involving many of the antibiotics mentioned in this article. He has been on advisory boards and received speaker honoraria from Pfizer, Wyeth, Novartis, Bayer, and Johnson & Johnson. A. T. Andrasevic has been an investigator in clinical trials involving many of the antibiotics mentioned in this article. She has received speaker honoria from MSD, Pfizer, Pliva, and Antiseptica. M. Bassetti has received speaker honoraria from Pfizer, Novartis, Sanofi-Aventis, GSK, Wyeth, MSD, Bayer, and Astellas. E. Bouza has received consulting and/or speaker honoraria from Pfizer, Novartis, Janssen, Baxter, McDonalds, Astellas, Wyeth Lederle, Optimer, and Gilead. He has received research support from Pfizer, Novartis, and Schering-Plough. J. Chastre has received consulting and speaker honoraria from Pfizer, Novartis, GSK, Wyeth, and Sanofi-Aventis. Brahms, Wyeth, Johnson & Johnson, Nektar-Bayer, and Arpida. G. Cornaglia has received speaker honoraria from Merck, Novartis, GSK, Pfizer, and Wyeth. S. Esposito has received consulting honoraria from Pfizer, Novartis, GSK, Wyeth, and Sanofi-Aventis. G. French has received speaker honoraria from Pfizer, Wyeth, GSK, Baxter, Destiny Pharma, Astellas, and Novartis. H. Giamarellou has received consulting honoraria from Pfizer, GSK, Wyeth, Novartis, Sanofi-Aventis, Merck, and Bayer. She has received research support from Pfizer, GSK, Wyeth, Novartis, Sanofi-Aventis, and Merck. I. C. Gyssens is on the board and guideline committee of the Dutch Working Party on Antibiotic Policy (SWAB) and Chair of the ESCMID Study Group for Antibiotic Policies (ESGAP). She is a consultant for the European Centre for Disease Prevention and Control (ECDC). Recent and relevant commercial relationships are: investigator in a clinical trial on moxifloxacin and research grant recipient from Bayer Healthcare; research grant recipient from Gilead/UCB Pharma, Merck Sharp & Dohme BV, and Bristol-Myers Squibb BV, The Netherlands; and scientific advisor receiving consulting honorarium from Pfizer and Wyeth. D. Nathwani has received honoraria for speaking at symposia and advisory boards organized by Wyeth, Johnson & Johnson, Novartis, Astellas, and Pfizer. He has received research support from Bayer and Pfizer. S. Unal has received consulting and/or speaker honoraria from Bayer, Pfizer and Wyeth. He has received research support from Novartis. A. Voss has received consulting and/or speaker honoraria from Pfizer, GSK, JohnsonDiversey, Cardinal Health, and Bio-Merieux.
PY - 2010/3
Y1 - 2010/3
N2 - Although the epidemiology of methicillin-resistant Staphylococcus aureus (MRSA) varies across Europe, healthcare-associated MRSA infections are common in many countries. Despite several national guidelines, the approach to treatment of MRSA infections varies across the continent, and there are multiple areas of management uncertainty for which there is little clinical evidence to guide practice. A faculty, convened to explore some of these areas, devised a survey that was used to compare the perspectives of infection specialists from across Europe on the management of MRSA infections with those of the faculty specialists. The survey instrument, a web-based questionnaire, was sent to 3840 registered delegates of the 19th European Congress of Clinical Microbiology and Infectious Diseases, held in April 2009. Of the 501 (13%) respondents to the survey, 84% were infection/microbiology specialists and 80% were from Europe. This article reports the survey results from European respondents, and shows a broad range of opinion and practice on a variety of issues pertaining to the management of minor and serious MRSA infections, such as pneumonia, bacteraemia, and skin and soft tissue infections. The issues include changing epidemiology, when and when not to treat, choice of treatment, and duration and route of treatment. The survey identified areas where practice can be improved and where further research is needed, and also identified areas of pan-European consensus of opinion that could be applied to European guidelines for the management of MRSA infection.
AB - Although the epidemiology of methicillin-resistant Staphylococcus aureus (MRSA) varies across Europe, healthcare-associated MRSA infections are common in many countries. Despite several national guidelines, the approach to treatment of MRSA infections varies across the continent, and there are multiple areas of management uncertainty for which there is little clinical evidence to guide practice. A faculty, convened to explore some of these areas, devised a survey that was used to compare the perspectives of infection specialists from across Europe on the management of MRSA infections with those of the faculty specialists. The survey instrument, a web-based questionnaire, was sent to 3840 registered delegates of the 19th European Congress of Clinical Microbiology and Infectious Diseases, held in April 2009. Of the 501 (13%) respondents to the survey, 84% were infection/microbiology specialists and 80% were from Europe. This article reports the survey results from European respondents, and shows a broad range of opinion and practice on a variety of issues pertaining to the management of minor and serious MRSA infections, such as pneumonia, bacteraemia, and skin and soft tissue infections. The issues include changing epidemiology, when and when not to treat, choice of treatment, and duration and route of treatment. The survey identified areas where practice can be improved and where further research is needed, and also identified areas of pan-European consensus of opinion that could be applied to European guidelines for the management of MRSA infection.
KW - Antibiotic management
KW - Bacteraemia
KW - Healthcare-associated pneumonia
KW - Methicillin-resistant Staphylococcus aureus
KW - Skin and soft tissue infection
U2 - 10.1111/j.1469-0691.2010.03135.x
DO - 10.1111/j.1469-0691.2010.03135.x
M3 - Article
AN - SCOPUS:76749129468
SN - 1198-743X
VL - 16
SP - 3
EP - 30
JO - Clinical Microbiology and Infection
JF - Clinical Microbiology and Infection
IS - SUPPL. 1
ER -